Cantargia Ab Is A Swedish Biotechnology Company Based In Lundspecializing In Antibody Based Therapies That Target Il1Rapinterleukin 1 Receptor Accessory Protein The Company Focuses On Developing Treatments For Cancerinflammatoryand Autoimmune Diseasesits Pipeline Includes Preclinical And Clinical Stage Candidates Aimed At Conditions Such As Leukemia And Solid Tumors Cantargia Utilizes Proprietary Antibody Platforms To Inhibit Il1Rapworking To Disrupt Disease Mechanismsthe Company Is Publicly Traded On Nasdaq Stockholm And Engages With Potential Pharmaceutical Partners For Drug Development And Commercializationled By Ceo Damian Marron And Cfo Patrik Renbladcantargia Is Committed To Advancing Its Research And Development Efforts In The Biotechnology Sector
